GHRP-2 vs GHRP-6
GHRP-2, GHRP-6, and Hexarelin are all growth hormone-releasing peptides (GHRPs) that stimulate GH secretion by activating ghrelin receptors (GHS-R1a) on the pituitary gland. While they share the same receptor target, they differ meaningfully in potency, side effect profiles, and practical usability. All three also elevate cortisol and prolactin to varying degrees -- a key distinction from Ipamorelin, which is the only GHRP that selectively releases GH without significant impact on these hormones. This three-way comparison helps clarify when each GHRP might be preferred and why many researchers ultimately choose Ipamorelin instead.
Side-by-Side Comparison
| Category | GHRP-2 | GHRP-6 |
|---|---|---|
| Mechanism of action | GHRP-2 (Pralmorelin): Synthetic hexapeptide that activates GHS-R1a ghrelin receptors on the pituitary to trigger GH release. Produces a strong GH pulse with moderate appetite stimulation. Also elevates cortisol and prolactin, though less than GHRP-6 for appetite and less than Hexarelin for GH ceiling. | GHRP-6: The original GHRP. Activates the same ghrelin receptors but with the strongest appetite-stimulating effect of the three -- it potently mimics ghrelin's orexigenic signaling. Produces moderate GH release. Significantly elevates cortisol and prolactin. The intense hunger effect is either a benefit (for those trying to gain weight) or a significant drawback. |
| Primary research area | Growth hormone deficiency diagnosis (approved in Japan as a GH provocative test under the name Pralmorelin). Body composition research, GH secretion studies. Considered the best-balanced GHRP for potency vs side effects. | GH deficiency research, appetite stimulation, body composition. Historically the most widely studied GHRP. Often used in bulking protocols specifically because of the appetite increase. |
| Evidence level | Approved in Japan as a diagnostic agent (Pralmorelin/GHRP Kaken 100). Published human pharmacokinetic and pharmacodynamic data. Multiple studies characterizing its GH, cortisol, and prolactin responses. Not FDA-approved in the US. | Extensively studied in humans since the 1990s. Bowers et al. (multiple publications) established the foundational GHRP research. Published human data on GH release kinetics, appetite effects, and hormonal side effects. Not FDA-approved. |
| Administration route | Subcutaneous or intravenous injection. Typically 2-3 times daily, with the most important dose before bed. | Subcutaneous or intravenous injection. Typically 2-3 times daily. Often dosed 20-30 minutes before meals to leverage the appetite effect. |
| Typical research dosing | 100-300 mcg subcutaneous, 2-3 times daily. 8-12 week cycles with breaks to prevent desensitization. | 100-300 mcg subcutaneous, 2-3 times daily. Same cycling approach. Often paired with food timing due to appetite spike ~20 minutes post-injection. |
| Key studies/evidence | Bowers et al. -- comparative GHRP studies establishing the potency hierarchy. Copinschi et al. (1996) -- human GH release data for GHRP-2. Laferrere et al. (2005) -- GHRP-2 effects on body composition. Japanese regulatory approval data for diagnostic use (Pralmorelin). | Bowers (1998) -- foundational review of GH secretagogues. Arvat et al. (1997) -- comparative GH release and side effect profiling. Mericq et al. (2003) -- GHRP-6 effects on GH secretion patterns. Extensive PK/PD data from decades of research use. |
Can They Be Stacked?
Combining multiple GHRPs is generally not recommended. They all compete for the same GHS-R1a ghrelin receptor, so combining them does not produce additive GH release -- it mainly amplifies cortisol and prolactin side effects. The better stacking strategy is to pair one GHRP with a GHRH analog (like CJC-1295) to activate complementary receptor pathways for synergistic GH release. GHRP-2 + CJC-1295 is the most common pairing when stronger GH output than Ipamorelin + CJC-1295 is desired.
Verdict
Among the three classic GHRPs, GHRP-2 offers the best balance of GH potency and manageable side effects -- it is the most commonly recommended if a stronger GH pulse than Ipamorelin is desired. GHRP-6 is the go-to for researchers who want appetite stimulation alongside GH release (bulking contexts), but the intense hunger and higher cortisol/prolactin elevation limit its appeal. Hexarelin produces the strongest acute GH pulse of any GHRP but suffers from rapid receptor desensitization (tolerance within 4-8 weeks), making it impractical for sustained use. All three elevate cortisol and prolactin, which requires monitoring with extended use and distinguishes them from Ipamorelin -- the cleanest GHRP with selective GH release and no meaningful cortisol/prolactin impact. For most research and clinical purposes, Ipamorelin (often paired with CJC-1295) has largely replaced these older GHRPs due to its superior side-effect profile, though GHRP-2 remains relevant when a more potent GH stimulus is specifically needed.
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.